Raj Dua

Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.

Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA.

Resolve Therapeutics LLC operates as a biotechnology company. It engages in the development of biotechnology drugs. The firm specializes in treatment of debilitating autoimmune diseases such as Systemic Lupus Erythematous and Sjogren’s syndrome. The company was founded by James Posada in 2010 and is headquartered in Seattle, WA.

Abacus Bioscience, Inc. develops developing novel immunotherapeutic treatments for cancer and antiviral diseases. The company was founded by Edward A Clark and Craig W Philips and is headquartered in Seattle, WA.